Mithra has an extensive expertise in the development of complex and long-acting innovative products using medical polymer technology.
Mithra has developed the contraceptive vaginal ring Myring® and Tibelia®, a tablet composed of tibolone used for hormone therapy in menopause. It focuses now on the development of a biodegradable subcutaneous implant, Zoreline®, for hormone-dependent cancers.
Polymer technology allows prolonged drug delivery based on the use of polymer matrices. These enable a drug’s active pharmaceutical ingredient (API) to be distributed at a predetermined rate over a period of time (from 1 month to 5 years), maintaining controlled drug delivery with minimum side effects.
It is used for various drug delivery strategies: intra-uterine devices, vaginal rings or implants. Little to no action is required by the patient, which improves compliance and therefore yields better results.
Myring® is a contraceptive vaginal ring made of ethylene-vinyl-acetate (EVA) copolymers which releases a combination of hormones.
Myring® has been marketed in Europe and Canada and was launched in the United States in January 2023.
Tibelia® is a tablet composed of tibolone, a synthetic steroid used for hormone therapy.
Tibelia® is already commercialized worldwide.
Zoreline® is a biodegradable subcutaneous implant for prostate cancer, breast cancer and benign gynecological indications (endometriosis, uterine fibroids).
Mithra is currently developing a one-month implant (3.6 mg goserelin) and a 3-month implant (10.8 mg goserelin).